SCHEMBL5489644

SCHEMBL5489644

O=C(O)C12CC3CC(CC(C3)C1)C2.[LiH]

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
PKM P14618 1/20 0.46
HTT P42858 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 2/20 0.43
THRB P10828 1/20 0.43
CYP2C9 P11712 1/20 0.43
EPHX1 P07099 1/20 0.42
EPHX2 P34913 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
GLA P06280 1/20 0.42
P2RX7 Q99572 1/20 0.41
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19557168 0.97 HSD11B1 (0.48) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL12714 0.97 HSD11B1 (0.48) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL19557166 0.97 HSD11B1 (0.48) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL5487496 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL5489940 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL4389277 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E
Hydrochloric Acid SCHEMBL1061147 0.94 L3MBTL1 (0.50) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL11460245 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL4947026 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E
SCHEMBL5487136 0.94 HSD11B1 (0.46) HSD11B1L3MBTL1PKMHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192875-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2021-12-07 US disclosed
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-12-17 US disclosed
US-10584109-B2 Processes for preparing antiviral compounds Gillead Pharmasset LLC (US) 2020-03-10 US disclosed
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-08-29 US disclosed
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2018-06-28 US disclosed
US-9890134-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2018-02-13 US disclosed
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-10-05 US disclosed
US-9670187-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2017-06-06 US disclosed
EP-3154984-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2017-04-19 EP disclosed
CN-106488920-A The preparation method of antiviral compound 吉利德制药有限责任公司 2017-03-08 CN disclosed
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
WO-2015191437-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2015-12-17 WO disclosed
US-8952204-B2 Sulfonium salt, method for producing the same, and photoacid generator DSP GOKYO FOOD & CHEMICAL CO., LTD. (JP) 2015-02-10 US disclosed
US-20140163254-A1 NOVEL SULFONIUM SALT, METHOD FOR PRODUCING THE SAME, AND PHOTOACID GENERATOR MP GOKYO FOOD & CHEMICAL CO., LTD. (JP) 2014-06-12 US disclosed
CN-101296893-A Diamondoid-based nucleating agents for thermoplastics CHEVRON USA INC (US) 2008-10-29 CN disclosed
US-20070037909-A1 Diamondoid-based nucleating agents for thermoplastics CHEVRON U.S.A. INC. (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10584109-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-11192875-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-20150361073-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 HSD11B1 2902/4885L3MBTL1 4079/4885PKM 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.